Zobrazeno 1 - 10
of 12
pro vyhledávání: '"María José García-Barchino"'
Autor:
Jon Celay, Teresa Lozano, Axel R. Concepcion, Elena Beltrán, Francesc Rudilla, María José García-Barchino, Eloy F. Robles, Obdulia Rabal, Irene de Miguel, Carlos Panizo, Noelia Casares, Julen Oyarzabal, Jesús Prieto, Juan F. Medina, Juan José Lasarte, José Ángel Martínez-Climent
Publikováno v:
Haematologica, Vol 103, Iss 6 (2018)
Regulatory T (Treg) cells can weaken antitumor immune responses, and inhibition of their function appears to be a promising therapeutic approach in cancer patients. Mice with targeted deletion of the gene encoding the Cl−/HCO3− anion exchanger AE
Externí odkaz:
https://doaj.org/article/25a1ce682baf49a699ef7d52c130573e
Autor:
Ana Patiño-García, Marc Garcia-Moure, Sonia Tejada-Solís, Marisol Gonzalez-Huarriz, Marie-Pierre Junier, Marta M. Alonso, Candelaria Gomez-Manzano, Montse Puigdelloses, Jose A. Martinez-Climent, Guillermo Aldave, Jaime Gállego Pérez-Larraya, Naiara Martinez-Velez, Hong Jiang, Luis Isaac Ramos, Maider Varela-Guruceaga, María José García-Barchino, Miguel Marigil, Hervé Chneiweiss, José Javier Aristu, Juan Fueyo, Elias A. El-Habr, Oren J. Becher, Alan Mackay, Michelle Monje, Virginia Laspidea, Marta Zalacain, Lucía Marrodán, Eric H. Raabe, Chris Jones, Ricardo Díez-Valle
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-10 (2019)
Nature Communications
Dadun. Depósito Académico Digital de la Universidad de Navarra
instname
Nature Communications
Dadun. Depósito Académico Digital de la Universidad de Navarra
instname
Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors in desperate need of a curative treatment. Oncolytic virotherapy is emerging as a solid therapeutic approach. Delta-24-RGD is a rep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76cc26eb97a32321dc9339616c186996
http://link.springer.com/article/10.1038/s41467-019-10043-0
http://link.springer.com/article/10.1038/s41467-019-10043-0
Autor:
Vicente Fresquet, Puri Fortes, Jon Celay, Julen Oyarzabal, Ruben Pio, María José Calasanz, Marta Larrayoz, Jose A. Martinez-Climent, Bruno Paiva, Alvaro Martínez-Baztan, María J. Moreno-Aliaga, Xabier Agirre, Oscar Yanes, Celia Prior, Carmen Vicente, María José Larrayoz, María José García-Barchino, Marta Fernández-Galilea, Jiahuai Han, Alexandra Junza, María D. Odero, Felipe Prosper, Carlos Panizo
Publikováno v:
Cancer discovery. 11(5)
For millions of years, endogenous retroelements have remained transcriptionally silent within mammalian genomes by epigenetic mechanisms. Modern anticancer therapies targeting the epigenetic machinery awaken retroelement expression, inducing antivira
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ed61c437c7076b826ba53cddee813fe
https://pubmed.ncbi.nlm.nih.gov/33355179
https://pubmed.ncbi.nlm.nih.gov/33355179
Autor:
Felipe Prosper, Ana Balanzategui, María José Larrayoz, Miguel A. Piris, Jose A. Martinez-Climent, Shuhua Yi, Sebastian Böttcher, Ken H. Young, María José Calasanz, Victor Segura, Antonio Martinez, Blanca Gonzalez-Farre, Marta Larrayoz, Cristina Jimenez, Davide Rossi, Jesús F. San Miguel, Jesús M. Hernández-Rivas, Julie Morscio, María José García-Barchino, Mingzhi Zhang, María Eugenia Sarasquete, Thomas Tousseyn, Marcos González, Alberto Orfao, Zijun Y. Xu-Monette, Santiago Montes-Moreno, Noemi Puig-Moron, Jon Celay, Miguel Alcoceba, Idoia Rodriguez, Xavier Sagaert, Bruno Paiva, Eloy F. Robles, Carlos Panizo, Gianluca Gaidano, Jianyong Li, Ricardo García-Muñoz, Sergio Roa, Vicente Fresquet, M. Rabasa
Publikováno v:
The Journal of Pathology. 245:61-73
The increased risk of Richter transformation (RT) in patients with chronic lymphocytic leukaemia (CLL) due to Epstein-Barr virus (EBV) reactivation during immunosuppressive therapy with fludarabine other targeted agents remains controversial. Among 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a70e78e5a7c17d3b87835dd36ce45b10
https://doi.org/10.1002/path.5060
https://doi.org/10.1002/path.5060
Autor:
Astrid Murumägi, Jose A. Martinez-Climent, Cor Lieftink, C. Michel Zwaan, María José García-Barchino, Roderick L. Beijersbergen, Maarten Fornerod, Maija Wolf, Olli Kallioniemi, Kimmo Porkka, Disha Malani, Diede Brunen, René Bernards, Noorjahan Jagalur Basheer
Publikováno v:
Oncotarget
Oncotarget, 7(25), 37407-37419. Impact Journals LLC
Oncotarget, 7(25), 37407-37419. Impact Journals LLC
Although conventional therapies for acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL) are effective in inducing remission, many patients relapse upon treatment. Hence, there is an urgent need for novel therapies. PIM kinases are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77e13ad1adb4ab9326c20ffc8872285b
https://doi.org/10.18632/oncotarget.9822
https://doi.org/10.18632/oncotarget.9822
Autor:
Yingying Liu, Edurne San José-Enériz, Leire Garate, Jose A. Martinez-Climent, Raúl F. Pérez, Elena Sáez, Pablo Santamarina, Xabier Agirre, María José García-Barchino, Estíbaliz Miranda, Sergio Roa, Raquel Ordoñez, Amaia Vilas-Zornoza, Irene de Miguel, Juan A. Sánchez-Arias, Ana Ugarte, Musheng Xu, Mario F. Fraga, Obdulia Rabal, Julen Oyarzabal, Felipe Prosper, Wei Wu
Publikováno v:
Journal of medicinal chemistry. 61(15)
Using knowledge- and structure-based approaches, we designed and synthesized reversible chemical probes that simultaneously inhibit the activity of two epigenetic targets, histone 3 lysine 9 methyltransferase (G9a) and DNA methyltransferases (DNMT),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18800942df446096b03a6a0ee2178016
https://pubmed.ncbi.nlm.nih.gov/29953809
https://pubmed.ncbi.nlm.nih.gov/29953809
Autor:
Jose A. Martinez-Climent, Obdulia Rabal, Francesc Rudilla, Julen Oyarzabal, Elena Beltran, Juan José Lasarte, Irene de Miguel, Noelia Casares, Teresa Lozano, Jon Celay, Carlos Panizo, Eloy F. Robles, Juan F. Medina, Jesús Prieto, Axel R. Concepcion, María José García-Barchino
Publikováno v:
Haematologica
Regulatory T (Treg) cells can weaken antitumor immune responses, and inhibition of their function appears to be a promising therapeutic approach in cancer patients. Mice with targeted deletion of the gene encoding the Cl-/HCO3- anion exchanger AE2 (a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b42323c0bb31dd62153b00036c7332c1
https://pubmed.ncbi.nlm.nih.gov/29191842
https://pubmed.ncbi.nlm.nih.gov/29191842
Autor:
Jose A. Martinez-Climent, Giancarlo Castellano, Xabier Agirre, María José García-Barchino, Estíbaliz Miranda, Victor Segura, Ander Estella-Hermoso de Mendoza, Edurne San José-Enériz, Matías A. Avila, Ramón Campos-Olivas, Clara M. Santiveri, José I. Martín-Subero, Juan A. Sánchez-Arias, Rosa María Alvarez, Juan José Lasarte, Juan R. Rodriguez-Madoz, Ana Ugarte, François-Xavier Ogi, Obdulia Rabal, Bruno Paiva, Sergio Roa, Maite Garcia Fernandez de Barrena, Felipe Prosper, Julen Oyarzabal, Amaia Vilas-Zornoza, Pierre Soule, Noelia Casares
Publikováno v:
Nature Communications
Nature Communications, Vol 8, Iss 1, Pp 1-10 (2017)
Repisalud
Instituto de Salud Carlos III (ISCIII)
Nature Communications, Vol 8, Iss 1, Pp 1-10 (2017)
Repisalud
Instituto de Salud Carlos III (ISCIII)
The indisputable role of epigenetics in cancer and the fact that epigenetic alterations can be reversed have favoured development of epigenetic drugs. In this study, we design and synthesize potent novel, selective and reversible chemical probes that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9cad4d3884df9ce07670a7f38efa651
https://doi.org/10.1038/ncomms15424
https://doi.org/10.1038/ncomms15424
Autor:
Jose A. Martinez-Climent, Vicente Fresquet, María José García-Barchino, Melissa Rieger, Carlo Carolis
Publikováno v:
Blood. 123:4111-4119
Acquired resistance to targeted drugs is emerging as an obstacle to successful cancer treatment. Recently, a BCL2-selective BH3 mimetic termed ABT-199 showed promising therapeutic results in BCL2-dependent tumors. Based on its high affinity for BCL2,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3489d749b1e95a890a59da6eaad2f8e6
https://doi.org/10.1182/blood-2014-03-560284
https://doi.org/10.1182/blood-2014-03-560284
Autor:
Ibai Goicoechea, Diego Alignani, Cristina Pérez Ruiz, Amaia Vilas-Zornoza, Cirino Botta, Juan José Garcés, Ramón García-Sanz, Bruno Paiva, Sonia Garate, Jose A. Martinez-Climent, María José Calasanz, Marta Larrayoz, María José Larrayoz, Sara Rodriguez, Marina Motta, Christian Reinhardt, Isidro Sánchez-García, Rafael Valdés-Mas, Yolanda R. Carrasco, Susana Constantino Rosa Santos, Aitziber López, Sarvide Sarai, Antonio Sacco, Aldo M. Roccaro, Massimo Gentile, María José García-Barchino, Catarina Geraldes, Sara Duarte, Jesús F. San-Miguel, Helena Vitória, Giuseppe Rossi, Cristina Jimenez, Felipe Prosper, Artur Paiva, Jon Celay
Publikováno v:
Blood. 134:1527-1527
Background: The transformation from a normal to a cancer cell is driven by the multistep acquisition of genetic alterations. Recently, shared mutations between clonal B cells in MBL/CLL and CD34+ hematopoietic progenitor cells (HPC) have been identif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b71dd281b65773b68ee4ebedc4cd3821
https://doi.org/10.1182/blood-2019-126889
https://doi.org/10.1182/blood-2019-126889